MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2023.03.006

Медицинская библиотека · Clinical genitourinary cancer · 2023

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).

Santoni Matteo, Massari Francesco, Myint Zin W, Iacovelli Roberto, Pichler Martin, Basso Umberto, Kopecky Jindrich, Kucharz Jakub, Buti Sebastiano, Salfi Alessia, Büttner Thomas, De Giorgi Ugo, Kanesvaran Ravindran, Fiala Ondřej, Grande Enrique, Zucali Paolo Andrea, Fornarini Giuseppe, Bourlon Maria T, Scagliarini Sarah, Molina-Cerrillo Javier, Aurilio Gaetano, Matrana Marc R, Pichler Renate, Cattrini Carlo, Büchler Tomas, Seront Emmanuel, Calabrò Fabio, Pinto Alvaro, Berardi Rossana, Zgura Anca, Mammone Giulia, Ansari Jawaher, Atzori Francesco, Chiari Rita, Zakopoulou Roubini, Caffo Orazio, Procopio Giuseppe, Bassanelli Maria, Zampiva Ilaria, Messina Carlo, Küronya Zsófia, Mosca Alessandra, Bhuva Dipen, Vau Nuno, Incorvaia Lorena, Rebuzzi Sara Elena, Roviello Giandomenico, Zabalza Ignacio Ortego, Rizzo Alessandro, Mollica Veronica, Catalini Ilaria, Monteiro Fernando Sabino M, Montironi Rodolfo, Battelli Nicola, Rizzo Mimma, Porta Camillo

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC).

PATIENTS AND

METHODS

Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the rate of partial/complete responses and stable disease. Univariate and multivariate analyses were used to explore the association of variables of interest with survival.

RESULTS

A total of 675 patients were included; BMI was >25 kg/m2 in 345 patients (51%) and was associated with improved OS (55.7 vs. 28.4 months, P < .001). The OCB of patients with BMI >25 kg/m2 versus those with BMI ≤25 kg/m2 was significantly higher only in patients with nonclear cell histology (81% vs. 65%, P = .011), and patients with liver metastases (76% vs. 58%, P = .007), Neutrophil to lymphocyte ratio >4 (77% vs 62%, P = .022) or treated by nivolumab plus ipilimumab (77% vs. 64%, P = .044). In the BMI ≤25 kg/m2 subgroup, significant differences were found between patients with NLR >4 versus ≤4 (62% vs. 82%, P = .002) and patients treated by IO+IO versus IO+TKIs combinations (64% vs. 83%, P = .002).

CONCLUSION

Our study suggests that the prognostic significance and the association of BMI with treatment outcome varies across clinico-pathological mRCC subgroups.

Для цитирования: Santoni Matteo, Massari Francesco, Myint Zin W, Iacovelli Roberto, Pichler Martin, Basso Umberto, Kopecky Jindrich, Kucharz Jakub, Buti Sebastiano, Salfi Alessia, Büttner Thomas, De Giorgi Ugo, Kanesvaran Ravindran, Fiala Ondřej, Grande Enrique, Zucali Paolo Andrea, Fornarini Giuseppe, Bourlon Maria T, Scagliarini Sarah, Molina-Cerrillo Javier, Aurilio Gaetano, Matrana Marc R, Pichler Renate, Cattrini Carlo, Büchler Tomas, Seront Emmanuel, Calabrò Fabio, Pinto Alvaro, Berardi Rossana, Zgura Anca, Mammone Giulia, Ansari Jawaher, Atzori Francesco, Chiari Rita, Zakopoulou Roubini, Caffo Orazio, Procopio Giuseppe, Bassanelli Maria, Zampiva Ilaria, Messina Carlo, Küronya Zsófia, Mosca Alessandra, Bhuva Dipen, Vau Nuno, Incorvaia Lorena, Rebuzzi Sara Elena, Roviello Giandomenico, Zabalza Ignacio Ortego, Rizzo Alessandro, Mollica Veronica, Catalini Ilaria, Monteiro Fernando Sabino M, Montironi Rodolfo, Battelli Nicola, Rizzo Mimma, Porta Camillo. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).. Clinical genitourinary cancer. 2023. DOI: 10.1016/j.clgc.2023.03.006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.